PSNL News and Press, Personalis Inc. From 06/13/23

Personalis, Inc. (Nasdaq: PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having p...

New findings emphasize the potential of company’s ultra-sensitive MRD platform for longitudinal disease monitoring and the study of dynamic tumor evolution Personalis, Inc. (Nasdaq: PSNL) today announced it will present new clinical data as scientific posters at the American Soci...

Multicenter VOLTAGE-2 Phase II Trial Will Conduct Exploratory Biomarker Analysis Using Highly-Sensitive Genomic Platforms from Personalis Personalis, Inc. (Nasdaq: PSNL), National Cancer Center, and Ono Pharmaceutical Co., Ltd. today announced they have entered into a collaborative agre...

2023-05-03 22:23:03 ET Personalis, Inc. (PSNL) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Caroline Corner – Investor Relations Chris Hall – Chief Executive Officer and President Aaron Tachibana – Chief Financ...

2023-05-03 16:40:37 ET Personalis press release ( NASDAQ: PSNL ): Q1 GAAP EPS of -$0.61 misses by $0.05 . Revenue of $18.9M (+24.1% Y/Y) beats by $1.55M . Cash, cash equivalents, and short-term investments of $148.9 million as of March 31, 2023 Personalis...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights. Recent Business Updates Announced a collaboration with Cancer Research UK, Univ...

Personalis, Inc. (Nasdaq: PSNL) today announced it has partnered with the Academic Breast Cancer Consortium (ABRCC) and Criterium to carry out a prospective clinical trial, B-STRONGER-1 (Breast Cancer-Minimal Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phas...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m....

2023-04-17 13:11:50 ET Summary Today, we put diagnostic firm Personalis, Inc. back in the spotlight as the shares go for less than the company's net cash on the balance sheet. The company has brought in a new CEO and announced significant cost saving measures. An updated inves...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19 at 3:00 p.m. Eastern Time. About Personalis, Inc. At ...